Glenmark’s current portfolio consists of 116 products authorised for distribution in the US marketplace
Glenmark has been granted final approval by the US FDA for triamcinolone acetonide ointment USP, 0.5 per cent, the generic version of triamcinolone acetonide ointment USP, 0.5 per cent of Perrigo New York.
According to IMS Health sales data for the 12 month period ending May 2016, the triamcinolone acetonide ointment USP, 0.5 per cent market achieved annual sales of approximately $4.4 million.
Glenmark’s current portfolio consists of 116 products authorised for distribution in the US marketplace and 61 ANDA’s pending approval with the US FDA.